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Study Objective: Animal data suggest that 9∆ -TetraHydroCannabinol ( 9∆ THC) stabilizes
autonomic output during sleep, reduces spontaneous sleep-disordered breathing, and
blocks serotonin-induced exacerbation of sleep apnea. On this basis, we examined the
safety, tolerability, and efficacy of dronabinol ( 9∆ THC), an exogenous Cannabinoid type
1 and type 2 (CB1 and CB2) receptor agonist in patients with Obstructive Sleep Apnea
(OSA). Design and Setting: Proof of concept; single-center dose-escalation study of dron-
abinol. Participants: Seventeen adults with a baseline Apnea Hypopnea Index (AHI)≥15/h.
Baseline polysomnography (PSG) was performed after a 7-day washout of Continuous Pos-
itive Airway Pressure treatment. Intervention: Dronabinol was administered after baseline
PSG, starting at 2.5 mg once daily. The dose was increased weekly, as tolerated, to 5 mg
and finally to 10 mg once daily. Measurements and Results: Repeat PSG assessments
were performed on nights 7, 14, and 21 of dronabinol treatment. Change in AHI (∆AHI,
mean ± SD) was significant from baseline to night 21 (−14.1±17.5; p = 0.007). No degra-
dation of sleep architecture or serious adverse events was noted. Conclusion: Dronabinol
treatment is safe and well-tolerated in OSA patients at doses of 2.5–10 mg daily and sig-
nificantly reduces AHI in the short-term. These findings should be confirmed in a larger
study in order to identify sub-populations with OSA that may benefit from cannabimimetic
pharmacologic therapy.
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INTRODUCTION
Pharmacologic treatment for Obstructive Sleep Apnea (OSA) is
limited (Smith et al., 2006), due to the complexity of the neu-
rochemical control and neuromodulation of central respiratory
drive and the upper airway motor output (Carley and Radulovacki,
2008). Nevertheless, the poor tolerance and long-term adherence
to Continuous Positive Airway Pressure (CPAP) treatment in OSA
(Weaver and Grunstein, 2008), make discovery of such therapeutic
alternatives clinically relevant and important.
Basic investigations support a strong neuromodulatory role
of endocannabinoids on autonomic cardio-respiratory functions,
which maybe distinct based on location (central vs. peripheral ner-
vous system; Padley et al., 2003; Kopczynska, 2007), interactions
with other neurotransmitters pertinent to sleep-wake behaviors
(Di Marzo et al., 1998), and possibly specific receptor subtypes
(Lin and Lee, 2002). The interaction of cannabinoid and seroton-
ergic pathways is complex (Kimura et al., 1998; Cheer et al., 1999)
and likely modified by similar factors. Animal data suggest that
cannabinoid agonists improve respiratory stability and this effect
maybe mediated by antagonism of peripheral serotonergic activity
(Fan, 1995; Carley et al., 2002).
We report a translational; proof of concept study aimed to test
the hypothesis that dronabinol, an exogenous CB1 and CB2 recep-
tor agonist can reduce abnormal respiratory events and associated
hypoxemia in patients with OSA. Dronabinol is FDA-approved as
an antiemetic and to treat cachexia. The primary objective was
to assess the safety and tolerability of dronabinol in patients with
moderate to severe OSA. Therefore, by design, dose-escalation of
dronabinol was permitted only if the lower dose was not associ-
ated with adverse events. Another experimental objective was to
test the effect of repeated doses of dronabinol on OSA severity
measured by Apnea Hypopnea Index (AHI).
MATERIALS AND METHODS
PARTICIPANTS
Consenting participants (ages 21–65 years) were drawn from a sin-
gle tertiary-care center referral population and underwent medical
and laboratory evaluations. After a clinically adequate 7-day period
of discontinuation of CPAP therapy (Kohler et al., 2011), a base-
line polysomnography (PSG) was performed and participants with
AHI≥ 15 were enrolled. Exclusion criteria included: arterial oxy-
gen saturation <75% for ≥5% of total sleep time on PSG; severe
symptomatic OSA precluding withdrawal of CPAP; surgical treat-
ment for OSA, shift work, significant weight-loss within 6 months,
and any uncontrolled medical disorder. This study was approved
by the IRB (UIC 2008-04294).
STUDY PROTOCOL
Forty-five participants were screened; 17 were enrolled and
treated with dronabinol. Participants were provided coded blister
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cards and instructed to self-administer one labeled pill 30 min
before bedtime nightly. The treatment period comprised of
dronabinol 2.5, 5.0, and 10.0 mg orally once daily for 7 days each
in succession as tolerated. Participants maintained a sleep/drug-
administration/adverse-event log daily. Follow-up PSG’s were per-
formed on nights 7, 14, and 21. Treatment adherence was assessed
by pill-count and venous blood assay of study drug at baseline and
on days 7, 14, and 21. Participants returned for a final visit after
21 days for re-institution of CPAP. Adverse events were assessed by
phone-calls twice-weekly and during weekly clinic visits. For 48 h
prior to each PSG the participants completed a Stanford Sleepiness
Scale (SSS) every 2 h while awake.
The participants were given ≥8 h time-in-bed for PSG’s with
standard instrumentation for electroencephalograms (C3/A2,
O2/A1), bilateral electrooculograms, electromyograms (submen-
tal, bilateral anterior tibial), electrocardiogram, oronasal airflow
(thermistor and nasal pressure transducer), thoracoabdominal
motions (piezo-crystal, EPM Systems), pulse oximetry, and body
position. Signals were acquired and processed using ALICE5®
(Respironics). Study medication was administered in the labo-
ratory on days 7, 14, and 21, 30 min before lights out.
Polysomnography’s were scored according to standard pub-
lished criteria by a single blinded technologist and board-certified
physician (American Sleep Disorders Association, 1992; The
Report of an American Academy of Sleep Medicine Task Force,
1999). Hypopneas were scored when a reduction in airflow
of >50% occurred and was associated with either an oxygen
desaturation of ≥3% or an arousal.
STATISTICAL ANALYSIS
Safety analysis was performed on participants who received at
least one dose of dronabinol. The efficacy evaluable population
included all participants completing at least 7 days of treatment
without non-compliance, including at least one on-treatment
repeat PSG. Non-compliance was failure to: return for study-visits,
administer or log >50% of study drug, or return study drug blis-
tercards/unused drugs. The primary efficacy measurement was
within-participant change in AHI (∆AHI) from baseline to day 21
of treatment. Other efficacy measures included∆AHI stratified by
sleep stage,body position,first-half vs. second half of the night, and
oximetry-based indices and sleep architecture. The distribution of
all primary and secondary efficacy measures was checked using
Anderson–Darling normality tests. The primary and secondary
efficacy measures were analyzed with paired two-sided t -tests. The
independent effects of the dose of dronabinol and baseline dis-
ease severity (AHI) on primary efficacy measure were examined
with ANCOVA. The stratified analyses were defined a priori and
no adjustment for multiple comparisons was employed for these
exploratory analyses. All analyses were performed using STATA 12
and a p-value of <0.05 was considered significant.
RESULTS
PRIMARY ENDPOINT: SAFETY
Baseline characteristics of subjects enrolled (n= 17) are shown in
Table 1. No serious adverse events (SAEs) were reported. Dose-
escalation was performed as directed by a board-certified sleep
physician who performed a history and physical examination on
days 8 and 15 (prior to each dose-escalation). Dose was held







Minutes SaO2 <85% 11.4 (18.5)#
Arousal Index 47.9 (26.1)#
Sleep efficiency 82.6 (9.0)#
#Data presented as mean (SD); *count data; Race:W, white; B, black; H, Hispanic;
O, other; SaO2, oxygen saturation by pulse oximetry; BMI, body mass index; AHI,
apnea hypopnea index.
Table 2 | Primary and secondary efficacy outcomes: within-subjects
change in apnea hypopnea indices with dronabinol.
Parameter Baseline to 3 weeks
(n=15) Mean (SD)
95% CI
∆AHI −14.11 (17.56) −23.8, −4.4
REM ∆AHI −5.31 (20.84) −16.8, 6.2
NREM ∆AHI −16.31 (18.03) −26.3, −6.3
Supine ∆AHI −15.23 (23.03) −28.5, −1.9
Non-Supine ∆AHI −9.84 (16.58) −19.8, 0.2
∆AHI 1st Half −14.70 (23.79) −27.9, −1.5
∆AHI 2nd Half −14.92 (18.31) −25.0, −4.8
∆AHI, change in apnea hypopnea index at week 3 of dronabinol treatment com-
pared to baseline; REM, rapid eye movement sleep; NREM, non-rapid eye move-
ment sleep, 1st and 2nd Half, first and second 4 h of polysomnography recording
time; 95% CI, Confidence Interval for paired t-tests.
Bold entries signify statistically significant changes.
constant if minor adverse events or new symptoms potentially
related to study drug were reported. Treatment-emergent AEs were
reported in 76% of participants receiving 2.5 mg, 57% receiving
5 mg, and 75% receiving 10 mg of dronabinol. The most fre-
quent AE was somnolence (29% at 2.5 mg, 14% at 5 mg, and
50% at 10 mg dronabinol). Increased appetite was reported in
23% of participants at 2.5 mg dronabinol and appetite stim-
ulation was not reported with dose-escalation to 5 or 10 mg
of dronabinol. No significant change in weight was noted over
the 21-day treatment period in the dronabinol group (all doses;
mean± SD=−0.67 kg± 1.91 kg; p= 0.24). One participant was
withdrawn due to AE (palpitations) and one due to oxygen satu-
ration falling below 75% for >5% of the total sleep time on day 7
PSG (a participant with severe OSA at baseline, AHI= 93/h).
EFFICACY ENDPOINTS
All primary and secondary efficacy measures were normally dis-
tributed with the exception of non-Supine AHI and time in min-
utes with <85% oxygen saturation. Table 2 presents the overall
and stratified ∆AHI with 95% confidence intervals. A signifi-
cant reduction in AHI from baseline (mean± SD; −14.1± 17.5,
p= 0.003) was noted in 15 participants who completed 21 days of
dronabinol treatment per protocol. This effect was not significantly
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FIGURE 1 | Change in apnea hypopnea index from baseline to week 3.
modified by dose of dronabinol (p= 0.84), baseline severity of
OSA (baseline AHI; p= 0.88), or an interaction of dose and base-
line AHI (p= 0.76). Due to the small sample size of this proof
of concept study, we show the temporal change in AHI within
individual participants that tolerated dronabinol at any dose for
3 weeks in Figure 1. Although, this graph confirms the overall
trend toward reduction in AHI at 21 days of dronabinol treat-
ment, there appears to be heterogeneity in treatment response in
this small sample.
With oral dosing, the time to maximum plasma concentra-
tion of dronabinol varies from less than 30 to more than 120 min
due to dronabinol’s significant first pass hepatic metabolism
and high lipid solubility (initial half-life 2–6 h; Pertwee, 2009).
Treatment endpoints were thus stratified according to time of
night: first-half vs. second half; as well as REM vs. NREM sleep;
and supine vs. non-supine sleep. While the reductions in REM
AHI (−5.31± 20.8, p= 0.17) and non-supine AHI (−9.84± 16.6,
p= 0.05) were not significant from baseline to end of treatment
period, NREM AHI (−16.31± 18.0, p= 0.003) and supine AHI
(−15.23± 23.0, p= 0.02) were reduced significantly with 3 weeks
of dronabinol treatment. In addition, dronabinol treatment led
to significant reductions in AHI during the first-half of the night
(−14.70± 23.8, p= 0.03) as well as during the second half of the
night (−14.92± 18.3, p= 0.007).
OXIMETRY
Secondary endpoints to examine treatment-related improvement
in oxygen delivery included change from baseline to day 21 of
treatment in two measures: (1) time (minutes) spent with oxygen
saturation below 85% and (2) nadir oxygen saturation. Despite
improvements in AHI, dronabinol treatment did not lead to
numerical improvement in nadir oxygen saturation (0.0± 3.0,
p= 0.5) or any decrease in time below 85% oxygen saturation
in minutes (0.9± 3.8, p= 0.4).
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SLEEP ARCHITECTURE AND SLEEPINESS
The SSS scores at baseline were 3.44± 1.60 (mean± SD), which
improved to 2.99± 1.60 (p= 0.05). The dronabinol group showed
no significant changes in Sleep Efficiency at week 3 compared to
baseline (0.38± 11.3, p= 0.9). The Arousal Index showed no sig-
nificant change at 3 weeks of dronabinol treatment compared to
baseline (2.23± 19.2, p= 0.6). No significant changes were noted
in the duration of REM or slow wave sleep relative to baseline.
DISCUSSION
This pilot study supports the safety and tolerability of dronabi-
nol in patients with OSA. Dronabinol resulted in a significant
improvement in AHI compared to baseline, with an overall reduc-
tion by 32%, a response that if replicated, may be significant in
mild-moderate OSA. The therapeutic effect of dronabinol noted
in this translational study is concordant with previous animal data.
Pharmacologic modification of reflexes involving nodose ganglion
sensory neurons can stabilize inspiratory effort (Radulovacki et al.,
1998) and increase the tonic/phasic activity of the upper airway
dilator muscles (Fenik et al., 2001). The vagal afferent neurons in
the nodose ganglion are regulated by endocannabinoid systems.
These effects vary depending on the agonist used, its receptor bind-
ing affinity, site of action, and the route of administration. For
example, anandamide, an endogenous cannabinoid that binds to
CB1 as well as vanilloid receptors evokes apnea in awake and anes-
thetized rats when administered intravenously (Carley et al., 2002).
Another study demonstrated similar effects of HU-210 (a chem-
ical structurally related to ∆9-TetraHydroCannabinol, ∆9THC),
whereby its injection into the ventrolateral medulla of anesthetized
rats abolished phrenic nerve activity, resulting in apnea (Carley
et al., 2002). In contrast, ∆9THC, a non-selective cannabinoid
receptor (CB1 and CB2) agonist administered intraperitoneally
significantly alters vagal balance, stabilizes respiratory pattern,
and produces a dose-dependent reduction in sleep related respira-
tory event density in an established rat model of sleep-disordered
breathing (Carley et al., 2002). Additionally, ∆9THC completely
blocked the apnea-genesis produced by peripheral injection of
serotonin (which does not penetrate the blood brain barrier;
Carley et al., 2002), suggesting that CB receptors significantly mod-
ulate serotonin signaling in the peripheral nervous system. This
possibility is further supported by in vitro data demonstrating that
activation of CB1 receptors on isolated nodose ganglion neurons
inhibits depolarization of these neurons by serotonin (Fan, 1995).
These observations provide mechanistic insights into a potentially
therapeutic role for dronabinol (∆9THC) in patients with OSA.
Carley et al., in their preclinical study showed that ∆9THC
decreased respiratory rate across all sleep/wake states, with no
effect on tidal volume. Thus the reduction in spontaneous and
serotonin-related apnea by ∆9THC in this animal model was
unlikely to represent a respiratory stimulant effect. Consistent with
these observations, the treatment effects of dronabinol appear
to be influenced by body position. We observed a significant
effect in the supine AHI only, suggesting modulation of hypoglos-
sal motor output (i.e., upper airway collapsibility) may partially
account for the therapeutic effects of dronabinol. Similar sig-
nificant improvements were observed with dronabinol treatment
during NREM sleep, while no significant change in AHI was noted
in REM sleep. Animal data suggest that antagonism of peripheral
5-HT3 serotonin receptor activity (with ondansetron) suppresses
apnea and that this is a plausible pathway for similar effects
noted with ∆9THC. These animal data disclose effects, primar-
ily, on the expression of apnea during REM sleep. In contrast,
ondansetron and dronabinol appear to have no effect on REM
sleep apnea in humans. This discrepancy between animal obser-
vations and translational studies in patients with OSA, maybe due
to species-specific effects or a lack of comparable doses between
species. The absence of therapeutic effects of dronabinol on REM
AHI presents a potential limitation to this therapeutic strategy in
patients with OSA.
We did not observe concomitant improvement in oxygenation
indices, likely due to the small sample size and the heterogene-
ity in treatment response. A subjective improvement in daytime
sleepiness with dronabinol treatment was noted, suggesting a
clinically significant response maybe expected in selected popu-
lations with OSA syndrome. There were no statistically significant
treatment-related changes in sleep architecture compared to base-
line. However, the sample showed a mean sleep efficiency of 83%
at baseline, which is considered normal in the laboratory environ-
ment (possible ceiling-effect) and no significant degradation of
sleep architecture was noted. No serious treatment-related adverse
events were noted in this study. The majority of adverse events
were reported at the 2.5 mg dose (in the first week) and improved
subsequently.
LIMITATIONS
Although dronabinol is approved for clinical use in other chron-
ically ill populations, the tolerability of dronabinol specific to the
OSA populations is unknown,where daytime somnolence,noctur-
nal sleep degradation, and significant weight changes for example
are of particular concern. This was addressed in the protocol design
of this pilot study by permitting dose-escalation as clinically tol-
erated, recognizing that time and dose effects maybe potentially
confounded. Significant time-effects despite the short-duration of
this study and in the context of a pharmacologic intervention may
occur due to neuroplasticity or the achievement of steady-state
drug level responses. Our repeated weekly morning serum samples
for dronabinol levels were below the limit of detection (2 ng/ml)
in all samples: that is daily dosing with up to 10 mg dronabinol
did not result in accumulation of a steady-state plasma level of
the drug over 21 days, making time-effects due to drug accumula-
tion unlikely. The effect-size of the 10 mg dose in the fully escalated
group on AHI at 3 weeks (n= 8), was modest compared to baseline
(Cohen’s d = 0.56, effect-size= 0.27). Further studies are neces-
sary to determine optimal doses and timing of administration and
how these relate to sub-acute vs. chronic effects of dronabinol
on the expression of sleep-disordered breathing (potential neuro-
plasticity). The mechanisms of the potential therapeutic effects of
dronabinol noted in this proof of concept study in patients with
OSA remain hypothetical. Thus, direct quantification of the rel-
ative effects of dronabinol on central respiratory rhythmogenesis
vs. its influence on hypoglossal motor output in a larger study
merits consideration. This will refine the target sub-populations
of OSA ideally suited to this potential alternative therapeutic
approach.
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CONCLUSION
This proof of concept study demonstrates that dronabinol is safe,
well-tolerated, and reduces AHI by approximately a third over
3 weeks of oral administration. Dronabinol treatment may be a
viable alternative or adjunctive therapy in selected patients with
OSA. It will be important to reproduce these findings in fully pow-
ered parallel group’s studies to identify the effects of different dose-
levels and duration of dronabinol treatment in patients with OSA.
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